The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Health-related quality of life (HRQoL) in newly diagnosed patients (pts) with chronic phase chronic myelogenous leukemia (CP CML) treated with bosutinib (BOS) or imatinib (IM).
J. H. Lipton
No relevant relationships to disclose
P. C. Trask
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
D. Cella
No relevant relationships to disclose
L. Duvillie
Employment or Leadership Position - Pfizer
C. Powell
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
M. V. Ramanan
Other Remuneration - Pfizer
Z. Maslyak
No relevant relationships to disclose
D. Kim
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer